Reuters logo
5 months ago
BRIEF-Almirall presents new data from Tildrakizumab clinical development program
March 7, 2017 / 5:36 PM / 5 months ago

BRIEF-Almirall presents new data from Tildrakizumab clinical development program

1 Min Read

March 7 (Reuters) - Almirall SA:

* Says presented new analyses of phase 1 and pivotal phase 3 clinical trials of Tildrakizumab, an inhibitor IL-23p19 which is currently being evaluated in patients with moderate-to-severe plaque psoriasis, during an annual meeting of American Academy of Dermatology

* Says data from clinical trials demonstrates long-term efficacy of Tildrakizumab

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below